OR WAIT null SECS
Berkeley Research Group Director discusses what to expect at his upcoming session.
In an interview with Pharmaceutical Commerce editor Nicholas Saraceno, Andrew Brownlee, director, Berkeley Research Group, discusses what viewers can expect during his breakout session at Access Insights 2023.
Brownlee: What we'll be covering in the session tomorrow is an examination of how stakeholders have reacted to different changes in the 340B program. It's 30 years old now at this point. There have been quite a few in-function points throughout that time period. Particularly over the last three years, as the program has evolved at an increasingly rapid pace we'll be looking at how different stakeholders in the program have been reacting to those changes.